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OBJECTIVES This study was designed to clarify and resolve the clinical profile of older patients with
hypertrophic cardiomyopathy (HCM).
BACKGROUND Adverse consequences of HCM such as sudden death and incapacitating symptoms have been
emphasized for the young and middle-aged.
METHODS Long-term outcome of HCM was assessed in a community-based cohort not subject to
tertiary center referral bias.
RESULTS Of 312 patients, 73 (23%) achieved normal life expectancy (75 years; range to 96); 44 (14%)
were 80 years old. Most patients 75 years (47; 64%) experienced no or only mild limiting
symptoms and lived virtually their entire lives with few HCM-related clinical consequences;
26 patients (36%) experienced severe progressive symptoms. In elderly patients with HCM,
diagnosis and symptom onset were considerably delayed to 74  8 and 70  11 years,
respectively. For patients 50 years at diagnosis, the probability of survival for 5, 10, and 15
years was 85  3%, 74  4%, and 57  6%, respectively, and did not significantly differ from
a matched general population (p  0.20). Patients 75 years were predominantly women,
and had less marked wall thickness and more frequently showed basal outflow obstruction
30 mm Hg (compared with those 75 years; p  0.01 and 0.001, respectively).
CONCLUSIONS Hypertrophic cardiomyopathy is frequently well tolerated and compatible with normal life
expectancy, and may remain clinically dormant for long periods of time with symptoms and
initial diagnosis deferred until late in life. These observations afford a measure of reassurance
to many patients with HCM, a disease for which clinical course is often unfavorable and
unpredictable. (J Am Coll Cardiol 2003;42:882–8) © 2003 by the American College of
Cardiology Foundation
Hypertrophic cardiomyopathy (HCM) is a relatively com-
mon familial cardiac disease with a broad clinical spectrum
for which the risk of premature cardiovascular death and
incapacitating symptoms in young patients has been repeat-
edly emphasized (1–16). These unfavorable aspects of the
natural history of HCM, although applicable only to some
patient subsets, have nevertheless contributed importantly
to the mistaken perception that HCM is a generally adverse
disease that inevitably leads to sudden or heart failure-
related death or profound disability (5–10,12–15).
Although HCM has been regarded largely as a disease of
the young, its occurrence in elderly patients has been
acknowledged (17–21). However, the probability and fre-
quency with which HCM is consistent with extended
survival is not generally appreciated. Therefore, we have
analyzed a large HCM cohort not subject to tertiary
center-related referral bias (22), in order to develop a clinical
profile of the subset of patients with HCM notable for
achieving advanced age.
METHODS
Selection of patients. The Minneapolis Heart Institute is
a large community-based clinic and hospital service sup-
porting the Minneapolis-St. Paul metropolitan area (popu-
lation 3 million) and Minnesota (population 5 million).
Between 1981 and 2001, 312 consecutively enrolled patients
with HCM were evaluated, including 246 at the Minneap-
olis campus, 36 within the satellite clinic program, and 30 in
the Children’s Heart Clinic. Each of these patients resided
in Minnesota or the contiguous states of Wisconsin, Iowa,
North Dakota, and South Dakota and represent the con-
secutively evaluated HCM cohort at our institution not
specifically referred either to the senior author (B.J.M.), or
expressly evaluated for highly specialized HCM-related
care.
The initial clinical evaluation (and study entry) was taken
at the time the diagnosis of HCM was first established.
Most recent clinical assessment was obtained by 2001 and
the mean follow-up period was 10.2 7 years. Diagnosis of
HCM was based on the echocardiographic identification of
a hypertrophied, nondilated left ventricle (LV) (wall thick-
ness 15 mm in adults, and the equivalent relative to body
surface area in children), in the absence of another cardiac or
systemic disease capable of producing a similar magnitude of
hypertrophy (23).
No patient was included in the study group solely on the
basis of a diagnosis made during systematic pedigree anal-
ysis. Of the 312 patients, 280 were from separate pedigrees
and unrelated; the remaining 32 patients came from 15
other families. As is the convention in HCM (1–4,16),
onset of heart failure (HF)-related symptoms was treated
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with either beta-blockers or verapamil and occasionally
disopyramide. Amiodarone was administered in 18 patients
(6%), usually for control of atrial fibrillation.
Echocardiography. Echocardiographic data were taken
from the clinical assessment at or near the time of the initial
diagnostic evaluation. Studies were performed with com-
mercially available Hewlett-Packard Nos. 500, 2000, and
5500 instruments. Extent and distribution of LV hypertro-
phy were assessed as previously reported (23). In the
parasternal short axis, the LV was divided into four regions:
anterior and posterior ventricular septum and lateral and
posterior free wall (23).
Peak instantaneous LV outflow gradient was estimated
under basal conditions with continuous-wave Doppler (23).
Calcium accumulation in the mitral annular space was
graded qualitatively (1 to 4). Echocardiographic measure-
ments in each patient were made prospectively by one
observer (B.J.M.).
Statistical analysis. Data are expressed as mean  SD or
in proportions, where appropriate. Subgroups were com-
pared by Student t test for continuous variables, and by
chi-squared with the continuity (Yates) correction for cat-
egorical variables.
Estimation of survival in a sample of the general U.S.
population was based on U.S. mortality rates (24). Age- and
gender-appropriate risk rates were used to compute the
probability of death within each successive five-year interval
for each patient, or part thereof in the case of censoring
within that interval. The sum of these probabilities for
patients alive at the beginning of the respective intervals
represents the expected number of deaths, which was then
used to construct a survival curve according to the actuarial
method. The expected number of deaths during the
follow-up period was compared to the observed number by
the chi-squared test for a Poisson distribution (25).
The probability of survival (taking into account all-cause
mortality) 5, 10, 15, and 20 years after initial HCM
diagnosis was calculated for the overall cohort and for those
patients 50 years or 50 years old at diagnosis and
compared with the general population. In addition, the
specific influence of a history of systemic hypertension on
survival was tested, after adjustment for patient age at HCM
diagnosis, by Cox-regression analysis. P values of 0.05
were considered indicative of a significant difference; all
tests were two-sided.
RESULTS
Patients <75 years old. DEMOGRAPHICS. Of the 312 pa-
tients, 239 (77%) were 75 years of age at the most recent
evaluation or death (Table 1, Fig. 1); 156 (65%) were men.
Most patients (203; 85%) had experienced no or only mild
symptoms and were in New York Heart Association func-
tional classes I and II at most recent evaluation; only 36
(15%) had severe symptoms (classes III/VI). Age at initial
HCM diagnosis was 38  18 years (Table 1, Fig. 1).
OUTCOME. Of the 239 patients 75 years, 195 (83%)
survived to the end of the follow-up period. The remaining
41 patients died (17%), including 24 that were HCM-
related (Table 1).
LEFT VENTRICULAR HYPERTROPHY. Average maximum
LV wall thickness was 22  6 mm, including 81 (34%)
20 mm and 34 (14%) 30 mm (Table 1). Patients
commonly showed hypertrophy localized to one LV seg-
ment (88; 37%); 151 patients (63%) had more diffuse LV
hypertrophy involving two to four segments.
Patients >75 years old. DEMOGRAPHICS. Of the 312
study patients, 73 (23%) had survived to age 75 and beyond;
44 of these 73 patients achieved 80 years of age (ranging
to 96 years), comprising 14% of the overall study group
(Table 1, Fig. 1). Age of the patients in this subset was 83
 5 years at most recent evaluation or death. Age at initial
HCM diagnosis was considerably delayed to 74  8 years
(range 47 to 91).
Age at the onset of HCM-related symptoms was also
delayed to 70 11 years (range 25 to 91), including 44 (60%)
after age 70 (Table 1). At most recent evaluation, 47 patients
(64%) were asymptomatic or mildly symptomatic (classes I/II)
and 26 (36%) had severe symptoms (classes III/IV).
Most older patients were women (78%), significantly
exceeding that in younger study patients (35%; p  0.001)
(Table 1). Clinical presentation and the trigger for the
diagnostic echocardiographic study was onset of symptoms
in 65 (90%), a heart murmur in 6 (8%), and family history
of HCM in 1 (2%).
Outflow obstruction (gradient 30 mm Hg) was present
at or near the initial diagnostic evaluation in 35 of 73
patients (48%), exceeding that in patients 75 years of age
(25%; p  0.001) and was 50 mm Hg in 27 of these, with
range to 140 mm Hg (Fig. 2). Atrial fibrillation showed a
trend toward greater frequency in older patients 75 years
(25% vs.17%, respectively; p  ns).
There was no consistent relation between the presence of
mitral annular calcium and outflow obstruction. Of the 27
patients with large subaortic gradients50 mm Hg, only 12
(45%) had moderate-to-severe annular calcium; most of the
27 patients (15/27; 55%) showed either no or mild calcium
accumulation.
OUTCOME. Of the 73 study patients who had achieved age
75 or more, 46 (63%) were alive at the end of the follow-up
period; for 27 patients (37%) the follow-up ended with their
death, including 8 that were HCM-related: sudden in 2,
HF-related in 2, and the consequence of embolic stroke in
4 (Table 1).
Abbreviations and Acronyms
HCM  hypertrophic cardiomyopathy
HF  heart failure
LV  left ventricle
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Table 1. Comparison of Clinical, Demographic, and Echocardiographic Features With Respect
to Age in 312 Patients With HCM
Parameter
Age*
>75 Years <75 Years p Values
Patients 73 (23%) 239 (77%) —
Male gender 16 (22%) 156 (65%)  0.001
Age, initial HCM diagnosis 74  8 38  18 —
Age, most recent evaluation (or death) 83  5 49  18 —
Family history HCM 4 (5%) 68 (28%)  0.001
NYHA functional class (most recent evaluation) 0.001
I 13 (18%) 126 (53%)
II 34 (46%) 77 (32%)
III/IV 26 (36%) 36 (15%)
Age—at onset symptoms 70  11 37  18 —
Symptom onset  70 years 44 (60%) 2 (1%) —
LV outflow gradient ( 30 mm Hg) 35 (48%) 60 (25%) 0.001
Maximum LV wall thickness (mm) 20.6  3 22.0  6 0.01
LVID 42  7 43  8 0.11
Left atrium (mm) 43  8 42  10 0.19
Atrial fibrillation 18 (25%) 40 (17%) 0.17
Amiodarone 4 (6%) 14 (6%) 1.0
Hypertension 25 (34%) 27 (11%)  0.001
Deaths
HCM-related
Sudden 2 19 —
Heart failure 2 3 —
Stroke 4 2 —
Other cardiac/noncardiac 19 17 —
Major interventions
Septal myectomy/MVR 8 26 —
Pacemaker 12 9 —
ICD 0 14 —
Heart transplant 0 5 —
*Obtained at most recent evaluation or death, with exception of the echocardiographic measures which were obtained at or near
the time of the initial diagnostic evaluation.
HCM  hypertrophic cardiomyopathy; ICD  implantable cardioverter-defibrillator; LV  left ventricular; LVID  left
ventricular internal dimension at end-diastole; MVR  mitral valve replacement; NYHA  New York Heart Association.
Figure 1. Distribution of ages (at last evaluation or death) in 312 patients with hypertrophic cardiomyopathy (HCM), showing those patients who survived,
died of HCM-related causes, or died of causes unassociated with HCM.
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LEFT VENTRICULAR HYPERTROPHY. Left ventricular wall
thickness was significantly less than in younger patients
75 years (20.6  3 vs. 22.0  6 mm; p  0.01), including
30 (41%)20 mm; only one patient (1.4%) was30 mm in
thickness versus 34 patients (14%) 75 years old (p 
0.002) (Table 1). Patients achieving 75 years of age
commonly showed hypertrophy confined to one LV seg-
ment (31; 42%); 42 patients (58%) had more diffuse LV
hypertrophy involving two to four segments (all p  0.5 vs.
patients 75 years).
Survival probabilities. Probability of actuarial survival
(with respect to total all-cause mortality) was calculated
from the time of initial HCM diagnosis for all patients in
the study cohort (Table 2, Figs. 3 and 4). Likelihood of
survival after 5, 10, 15, and 20 years was 90  2, 82  2,
73  3, and 64  4 years, respectively, and the probability
of death during the study period was significantly reduced
compared to that of the general population (p  0.001)
(Table 2, Fig. 3).
Probability of survival was assessed separately in those
patients 50 years (mean 29  14) and 50 years (mean
66  10) at HCM diagnosis (Table 2, Fig. 4). For patients
identified earlier in life (50 years) survival at 5, 10, 15, and
20 years was 95  2, 90  3, 86  3, and 77  5, reduced
respectively compared to the general population (p 
0.001). However, for those patients diagnosed later in life
(50 years), the expectation for survival was 85  3,
74  4, 57  6, and 48  7 years, respectively, which did
not differ significantly from the general population and the
overall risks of living (p  0.20).
HCM patients with hypertension. Of the 312 study
patients, 52 (27 were75 years and 25 were75 years) had
a history of systemic hypertension, predominantly mild in
degree (150/90 mm Hg) (Table 3). Each of these patients
also had at least one other independent, objective clinical
marker most consistent with HCM to substantiate this
clinical diagnosis (Table 3). A history of systemic hyperten-
sion had no significant influence on survival in the analysis
of the overall study group (p  0.05).
DISCUSSION
Disability and premature sudden death have been estab-
lished as important consequences of HCM, with the occur-
rence of major disease complications emphasized for young
patients (5–16). Although survival to older ages has been
reported (17–21), the frequency and probability with which
HCM patients achieve advanced longevity (and the clinical
profile of such patients) remain incompletely defined.
Most published data on the clinical course of HCM
have emanated from tertiary center referral cohorts often
comprised of highly selected patients (2,4,5– 8,12–16,
18 –20,22,26,27). Indeed, such referral bias has importantly
influenced our perceptions of the overall HCM clinical
spectrum (1–4,16), owing to patient enrollments skewed to
younger high-risk individuals and those requiring special-
ized interventions such as surgery (1–4,16,22,26). For these
reasons, the subset of elderly patients with HCM, many
without substantial symptoms, has probably been underes-
timated in prior reports (22).
We have attempted to compensate for such prior deficits
in describing the overall HCM disease spectrum by offering
the present cross-sectional analysis in our large community-
based cohort of more than 300 patients with HCM not
subject to tertiary referral bias, and focusing on those
patients of advanced age. Such a HCM population is
particularly suitable for this purpose, and largely represen-
Table 2. Survival Probabilities in HCM Study Population
Patient Subset
Years From HCM Diagnosis
5 10 15 20
All patients* 90  2 (86, 93) 82  2 (77, 87) 73  3 (66, 79) 64  4 (56, 73)
General population (expected) 94 86 80 74
 50 years at diagnosis* 95  2 (91, 98) 90  3 (84, 95) 86  3 (79, 92) 77  5 (67, 86)
General population (expected) 99 97 95 92
50 years at diagnosis† 85  3 (78, 91) 74  4 (63, 82) 57  6 (45, 68) 48  7 (34, 63)
General population (expected) 88 73 60 47
Mean  SD; 95% confidence limits appear in parentheses. *Survival significantly different vs. general population; p  0.001. †Survival did not differ significantly vs. general
population; p  0.20.
HCM  hypertrophic cardiomyopathy.
Figure 2. Presence of basal left ventricular outflow tract gradient (LVOT)
(at or near the time of initial diagnostic evaluation) shown separately for
subaortic gradients of 30 to 49 mm Hg and 50 mm Hg. Expressed as the
proportion of patients in each age subgroup with outflow obstruction, and
depicted with respect to age at last evaluation (or death).
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tative of the overall disease state (1,3,16,21,22) by virtue of
minimal skewing toward high-risk patients.
We have made a number of observations in older patients
that support the view that HCM does not invariably or
usually infer adverse prognosis. First, a substantial propor-
tion of our cohort (almost 25%) achieved normal life
expectancy of at least 75 years of age, and remarkably about
60% of these patients survived well beyond to particularly
advanced ages of 80 to 96 years. Indeed, HCM patients
with diagnosis later in life (50 years; mean age 66  10)
survived 5, 10, and 15 years with a probability of 85%, 74%,
and 57%, respectively, an expectation not substantially
different from that of the general population given the
overall risks of living (24). Furthermore, about two-thirds of
our patients 75 years old experienced little or no symp-
toms of functional disability and achieved their extended
survival and quality of life without major interventions
(1–4,16,26,27). These observations underscore the diverse
natural history of HCM, which includes clinical presenta-
tion at virtually any age from infancy to the elderly and
compatibility with normal life expectancy.
We wish to emphasize, however, that because our cohort
is unavoidably hospital-based, the identification of all pa-
tients with HCM in our geographic region who achieved
Figure 3. Actuarial curves showing survival probabilities with respect to all causes of death for the hypertrophic cardiomyopathy (HCM) study population
from the time of initial diagnosis, compared to expected survival probabilities of an age- and gender-matched cohort from the U.S. general population
(Gen. Pop.) (24).
Figure 4. Actuarial curves showing survival probabilities with hypertrophic cardiomyopathy (HCM) with respect to all causes of death, from the time of
initial diagnosis. Shown separately for patients with HCM diagnosis 50 years and 50 years, and compared to expected survival probabilities of an age
and gender-matched cohort from the U.S. general population (Gen. Pop.) (24).
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advanced age was not possible. Also, we are not able to
ascertain the number of patients who died prematurely at
young ages and before clinical diagnosis (and potentially
would have been part of this cohort) (11,16,28). Conse-
quently, a precise calculation for the number of elderly
patients represented in our population of patients with
HCM at any particular cross-sectional point in time is
beyond the scope of the present investigation.
Second, whereas HCM is regarded as a genetic disorder
caused by sarcomeric protein mutations (1,3,16,29–31,34),
our data suggest that disease manifestations may neverthe-
less remain dormant for particularly long periods of time,
with clinical diagnosis frequently delayed until very late in
life. Therefore, it is possible for patients with HCM to live
virtually their entire lives without clinical evidence of their
disease. For example, almost one-half of our patients who
survived to at least 75 years developed HCM-related symp-
toms for the first time only after age 70. This long period of
clinical dormancy is striking, suggesting the alternative
possibility that phenotypic expression of HCM may evolve
later during adulthood, in midlife and beyond, as recently
reported with cross-sectional (28,29) and serial echocardio-
graphic analyses (30,32).
Third, survival to particularly advanced age was associ-
ated with relatively mild morphologic expression of the
HCM phenotype. This was demonstrable by the modest
degrees of LV wall thickening usually confined to only one
segment of the wall (20 mm, predominantly the anterior
septum), as well as the uncommon occurrence of extreme
LV hypertrophy with wall thickness 30 mm in only 1% of
our patients; the latter phenotypic expression is largely
confined to young patients, for whom it may represent a risk
factor for sudden death (11,12,15).
Fourth, of note, a substantial proportion of our HCM
patients of advanced age demonstrated outflow obstruction
under basal conditions with subaortic gradients 30 mm
Hg (33), including almost 50% of those 75 years and 33%
of those 80 years. Indeed, subaortic obstruction was
significantly more common in our older patients, of whom
about one-half were also free of marked symptoms. This
observation suggests that although LV outflow obstruction
has been associated with deleterious long-term conse-
quences such as progressive HF and death (33), it may also
be well tolerated over substantial periods of time in some
patients.
Because we cannot be certain regarding the duration over
which these outflow gradients have been present (given the
unavailability of serial echocardiographic studies spanning
many years), it is possible that, alternatively, outflow ob-
struction could develop late in life and represent a delayed
disease feature of HCM. However, the lack of correlation
between mitral annular calcium and subaortic obstruction
suggests that such accumulation of calcium with aging is not
a determinant of outflow gradients developing in elderly
patients with HCM (20).
The determinants of extended survival in some patients
with HCM are largely unresolved. It is possible that benign
genetic substrates may convey favorable prognosis and
normal life expectancy (29,30,34). However, at present,
genotype data are available for only a limited number of
elderly patients with HCM, with mutations in cardiac
myosin-binding protein C and troponin-I genes predomi-
nating (31).
Finally, we are cognizant of the potential ambiguities that
may surround the diagnostic assignment of nonobstructive
HCM to those patients of advanced age with modest LV
hypertrophy, because of the frequency with which systemic
hypertension occurs in this age group (35). However, in the
present study, each of the patients with a history of
hypertension also had 1 independent and objective mark-
ers characteristic of clinically expressed HCM and incon-
sistent with the modest level of hypertension observed (3).
Therefore, it is unlikely that the present HCM study cohort
is contaminated significantly by patients with hypertensive
heart disease unrelated to HCM.
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